Metastatic breast cancer is the second cause of cancer death in women, and effective therapeutic options are still limited up to date. In recent years, major advances in the field of cancer immunotherapy have emphasize the underlying therapeutic potential of immune checkpoint blockade and cancer vaccines, leading to a quest for tumor associated antigens. Somatic mutations or impaired RNA splicing in cancer cells are established sources of neoantigens, however the reactivation of unique developmental states in some cancers could also result in the generation of tumor-specific antigens capable of driving an adaptive immune response against malignant cells. Indeed, molecular profiling of breast cancers in mouse and human has revealed that some molecular subtypes share similarities with non-conventional mouse mammary stem cell populations. Here, we are exploring the possibility of a novel strategy for anti-cancer vaccination using these discoveries and specifically investigating the possibility to extend the current set of tumor associated antigens in breast cancer, with the identification a list of genes as candidates that are currently being tested in vitro and in vivo.
Metastatic breast cancer is the second cause of cancer death in women, and effective therapeutic options are still limited up to date. In recent years, major advances in the field of cancer immunotherapy have emphasize the underlying therapeutic potential of immune checkpoint blockade and cancer vaccines, leading to a quest for tumor associated antigens. Somatic mutations or impaired RNA splicing in cancer cells are established sources of neoantigens, however the reactivation of unique developmental states in some cancers could also result in the generation of tumor-specific antigens capable of driving an adaptive immune response against malignant cells. Indeed, molecular profiling of breast cancers in mouse and human has revealed that some molecular subtypes share similarities with non-conventional mouse mammary stem cell populations. Here, we are exploring the possibility of a novel strategy for anti-cancer vaccination using these discoveries and specifically investigating the possibility to extend the current set of tumor associated antigens in breast cancer, with the identification a list of genes as candidates that are currently being tested in vitro and in vivo.
Characterization of a novel immunogenic gene-expression program in breast cancer / Valente, Camilla. - (2023 Jun 21).
Characterization of a novel immunogenic gene-expression program in breast cancer
VALENTE, CAMILLA
2023
Abstract
Metastatic breast cancer is the second cause of cancer death in women, and effective therapeutic options are still limited up to date. In recent years, major advances in the field of cancer immunotherapy have emphasize the underlying therapeutic potential of immune checkpoint blockade and cancer vaccines, leading to a quest for tumor associated antigens. Somatic mutations or impaired RNA splicing in cancer cells are established sources of neoantigens, however the reactivation of unique developmental states in some cancers could also result in the generation of tumor-specific antigens capable of driving an adaptive immune response against malignant cells. Indeed, molecular profiling of breast cancers in mouse and human has revealed that some molecular subtypes share similarities with non-conventional mouse mammary stem cell populations. Here, we are exploring the possibility of a novel strategy for anti-cancer vaccination using these discoveries and specifically investigating the possibility to extend the current set of tumor associated antigens in breast cancer, with the identification a list of genes as candidates that are currently being tested in vitro and in vivo.File | Dimensione | Formato | |
---|---|---|---|
tesi_definitiva_Camilla_Valente.pdf
non disponibili
Descrizione: tesi_definitiva_Camilla_Valente
Tipologia:
Tesi di dottorato
Dimensione
38.92 MB
Formato
Adobe PDF
|
38.92 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.